rt-pcr exam for covid-19 negative during the screening visit. patients with an acute respiratory condition compatible with covid-19 being hospitalized; patients with an acute respiratory condition and with moderate to high probability of not being a covid infection 19; dyspnea secondary to other acute and chronic respiratory causes or infections (eg, decompensated chronic obstructive pulmonary disease, acute bronchitis, pneumonia, primary pulmonary arterial hypertension); severe respiratory clinical condition, presenting at least one of the criteria below: respiratory rate> 28 / min; arterial oxygen saturation < 92% with nasal oxygen therapy at 10 l/ min; pao2 / fio2 <300 mmhg 4. history of cardiac arrhythmia or long qt syndrome; 5. use of medications that are known to prolong qtc: citalopram, venlafaxine, bupropion and with no possibility of suspension during the period of investigational medical product administration. 6. inability to take oral medications; 7. patients on continuous use of amiodarone and / or pge5 inhibitors (ex .: sildenafil and similar). 8. use of digoxin, cyclosporine, cimetidine, tamoxifen. 9. use of anticonvulsants, antifungals, immunosuppressants other than corticotherapy. 10. use of hydroxychloroquine for other indications 11. use of chemoprophylaxis for malaria. 12. psoriasis in a form other than cutaneous 13. porphyria 14. use of protease inhibitors, ritonavir or cobicistat 15. clinical history of liver cirrhosis or child-pugh c classification; 16. patients with a history of degenerative retinal diseases (patients with retinal diseases due to diabetes and hypertension can participate in the research); 17. patient with a clinically relevant history of hearing loss; 18. patients with known severe degenerative neurological diseases and / or severe mental illness; 19. inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 20. known hypersensitivity and / or intolerance to hydroxychloroquine. 21. hypersensitivity and / or intolerance lopinavir / ritonavir -

rt-pcr exam for covid-19 negative during the screening visit. patients with an acute respiratory condition compatible with covid-19 being hospitalized; patients with an acute respiratory condition and with moderate to high probability of not being a covid infection 19; dyspnea secondary to other acute and chronic respiratory causes or infections (eg, decompensated chronic obstructive pulmonary disease, acute bronchitis, pneumonia, primary pulmonary arterial hypertension); severe respiratory clinical condition, presenting at least one of the criteria below: respiratory rate> 28 / min; arterial oxygen saturation < 92% with nasal oxygen therapy at 10 l/ min; pao2 / fio2 <300 mmhg 4. history of cardiac arrhythmia or long qt syndrome; 5. use of medications that are known to prolong qtc: citalopram, venlafaxine, bupropion and with no possibility of suspension during the period of investigational medical product administration. 6. inability to take oral medications; 7. patients on continuous use of amiodarone and / or pge5 inhibitors (ex .: sildenafil and similar). 8. use of digoxin, cyclosporine, cimetidine, tamoxifen. 9. use of anticonvulsants, antifungals, immunosuppressants other than corticotherapy. 10. use of hydroxychloroquine for other indications 11. use of chemoprophylaxis for malaria. 12. psoriasis in a form other than cutaneous 13. porphyria 14. use of protease inhibitors, ritonavir or cobicistat 15. clinical history of liver cirrhosis or child-pugh c classification; 16. patients with a history of degenerative retinal diseases (patients with retinal diseases due to diabetes and hypertension can participate in the research); 17. patient with a clinically relevant history of hearing loss; 18. patients with known severe degenerative neurological diseases and / or severe mental illness; 19. inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 20. known hypersensitivity and / or intolerance to hydroxychloroquine. 21. hypersensitivity and / or intolerance lopinavir / ritonavir -

1. rt-pcr exam for covid-19 negative during the screening visit. 2. patients with an acute respiratory condition compatible with covid-19 being hospitalized; 3. patients with an acute respiratory condition and with moderate to high probability of not being a covid infection 19; 4. dyspnea secondary to other acute and chronic respiratory causes or infections (eg, decompensated chronic obstructive pulmonary disease, acute bronchitis, pneumonia, primary pulmonary arterial hypertension); 5. severe respiratory clinical condition, presenting at least one of the criteria below: 1. respiratory rate> 28 / min; 2. arterial oxygen saturation < 92% with nasal oxygen therapy at 10 l/ min; 3. pao2 / fio2 <300 mmhg 4. history of cardiac arrhythmia or long qt syndrome; 5. use of medications that are known to prolong qtc: citalopram, venlafaxine, bupropion and with no possibility of suspension during the period of investigational medical product administration. 6. inability to take oral medications; 7. patients on continuous use of amiodarone and / or pge5 inhibitors (ex .: sildenafil and similar). 8. use of digoxin, cyclosporine, cimetidine, tamoxifen. 9. use of anticonvulsants, antifungals, immunosuppressants other than corticotherapy. 10. use of hydroxychloroquine for other indications 11. use of chemoprophylaxis for malaria. 12. psoriasis in a form other than cutaneous 13. porphyria 14. use of protease inhibitors, ritonavir or cobicistat 15. clinical history of liver cirrhosis or child-pugh c classification; 16. patients with a history of degenerative retinal diseases (patients with retinal diseases due to diabetes and hypertension can participate in the research); 17. patient with a clinically relevant history of hearing loss; 18. patients with known severe degenerative neurological diseases and / or severe mental illness; 19. inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 20. known hypersensitivity and / or intolerance to hydroxychloroquine. 21. hypersensitivity and / or intolerance lopinavir / ritonavir -

1. rt-pcr exam for covid-19 negative during the screening visit. 2. patients with an acute respiratory condition compatible with covid-19 being hospitalized; 3. patients with an acute respiratory condition and with moderate to high probability of not being a covid infection 19; 4. dyspnea secondary to other acute and chronic respiratory causes or infections (eg, decompensated chronic obstructive pulmonary disease, acute bronchitis, pneumonia, primary pulmonary arterial hypertension); 5. severe respiratory clinical condition, presenting at least one of the criteria below: 1. respiratory rate> 28 / min; 2. arterial oxygen saturation < 92% with nasal oxygen therapy at 10 l/ min; 3. pao2 / fio2 <300 mmhg 4. history of cardiac arrhythmia or long qt syndrome; 5. use of medications that are known to prolong qtc: citalopram, venlafaxine, bupropion and with no possibility of suspension during the period of investigational medical product administration. 6. inability to take oral medications; 7. patients on continuous use of amiodarone and / or pge5 inhibitors (ex .: sildenafil and similar). 8. use of digoxin, cyclosporine, cimetidine, tamoxifen. 9. use of anticonvulsants, antifungals, immunosuppressants other than corticotherapy. 10. use of hydroxychloroquine for other indications 11. use of chemoprophylaxis for malaria. 12. psoriasis in a form other than cutaneous 13. porphyria 14. use of protease inhibitors, ritonavir or cobicistat 15. clinical history of liver cirrhosis or child-pugh c classification; 16. patients with a history of degenerative retinal diseases (patients with retinal diseases due to diabetes and hypertension can participate in the research); 17. patient with a clinically relevant history of hearing loss; 18. patients with known severe degenerative neurological diseases and / or severe mental illness; 19. inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 20. known hypersensitivity and / or intolerance to hydroxychloroquine. 21. hypersensitivity and / or intolerance lopinavir / ritonavir -